All Points West

In this episode of the All Points West podcast, we sit down with Lindy Durrant, the founder and CEO of AIM-listed ScanCell. Since co-founding ScanCell in 1997, Lindy has been at the forefront of developing groundbreaking immunotherapies for cancer and infectious diseases. With over 25 years of experience in translational research, she has played a pivotal role in bringing monoclonal antibodies and cancer vaccines from the lab to clinical trials. We discuss the rapidly growing immuno-oncology market, the potential of ScanCell's GlyMab platform, and what the future holds for cancer treatment. 

What is All Points West?

The All Points West podcast meets leaders from some of the most innovative and influential small and mid-cap UK-listed companies to learn more about them and their businesses. Hosted by former Sunday Times business journalist, Karl West.

Want to get in touch? Send an email to apw@stbridespartners.co.uk

Nothing in this podcast is intended as investment advice and the people in this podcast may hold positions in the stocks they talk about. Do not buy anything based solely on a tip or recommendation. Please do your own research.